Quyen-Quyen do

Quyen-Quyen Do is a Senior Scientist at Zentalis Pharmaceuticals, with extensive experience in the pharmaceutical industry, previously holding senior roles at Cidara Therapeutics and Arena Pharmaceuticals, Inc. Notable achievements include the successful scaling of the optically pure candidate ADP418, leading to its FDA fast track designation and current Phase I clinical trial for acute heart failure. Quyen-Quyen's expertise encompasses multi-step synthetic processes, optimization of synthetic routes, and the discovery of novel compounds for cardiovascular treatments. Educational credentials include a Master of Science in Organic Chemistry and a Bachelor of Science in Biochemistry & Chemistry from UC San Diego, complemented by an ADMET Certificate from UCSD Extension.